GU Cancers 2025 | Advancing ctDNA testing in renal cancer

Alan Tan • 14 Feb 2025

GU Cancers 2025

Alan Tan, MD, Vanderbilt Ingram Cancer Center, Nashville, TN, reviews findings from a recent study on circulating tumor (ctDNA) testing in metastatic renal cell carcinoma. The study highlights that while kidney cancer has been considered a poor ctDNA shedder, higher-risk metastases (e.g., liver and bone) show detectable ctDNA. This research paves the way for deeper sequencing and potential treatment de-escalation strategies based on ctDNA profiling. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.